Literature DB >> 2027475

"Early" initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease.

J M Cedarbaum1, S E Gandy, F H McDowell.   

Abstract

We reviewed the histories of patients seen in a large Parkinson's disease clinic from 1983 to 1989 to determine if there is a relationship between the timing of initiation of levodopa therapy and the development of motor response fluctuations, dyskinesias, and dementia. There were no factors predisposing to the development of response fluctuations or dementia. Younger age at disease onset predisposed to the development of dyskinesia. Dyskinesias occurred in a greater proportion of patients in whom the initiation of levodopa therapy was delayed by more than 2 years from disease diagnosis than among those in whom treatment was started earlier. We thus failed to identify any adverse consequences of early levodopa treatment in our patient population.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2027475     DOI: 10.1212/wnl.41.5.622

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  15 in total

Review 1.  Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias.

Authors:  R C Dodel; K Berger; W H Oertel
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

2.  Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells.

Authors:  M C Coldwell; I Boyfield; T Brown; J J Hagan; D N Middlemiss
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

Review 3.  Drug management of Parkinson's disease.

Authors:  A Kishore; B J Snow
Journal:  Can Fam Physician       Date:  1996-05       Impact factor: 3.275

Review 4.  Early detection of Parkinson's disease. Implications for treatment.

Authors:  R Di Paola; R J Uitti
Journal:  Drugs Aging       Date:  1996-09       Impact factor: 3.923

5.  Motor fluctuations and dyskinesias in advanced/end stage Parkinson's disease: a study from a population of brain donors.

Authors:  S Papapetropoulos; D C Mash
Journal:  J Neural Transm (Vienna)       Date:  2006-12-07       Impact factor: 3.575

6.  A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.

Authors:  J L Montastruc; O Rascol; J M Senard; A Rascol
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-09       Impact factor: 10.154

Review 7.  Levodopa in Parkinson's disease: neurotoxicity issue laid to rest?

Authors:  M G Murer; R Raisman-Vozari; O Gershanik
Journal:  Drug Saf       Date:  1999-11       Impact factor: 5.606

8.  Combined treatment with acupuncture reduces effective dose and alleviates adverse effect of L-dopa by normalizing Parkinson's disease-induced neurochemical imbalance.

Authors:  Seung-Nam Kim; Ah-Reum Doo; Ji-Yeun Park; Hyunwoo J Choo; Insop Shim; Jongbae J Park; Younbyoung Chae; Bena Lee; Hyejung Lee; Hi-Joon Park
Journal:  Brain Res       Date:  2013-12-07       Impact factor: 3.252

Review 9.  Idiopathic Parkinson's disease: epidemiology, diagnosis and management.

Authors:  Y Ben-Shlomo; K Sieradzan
Journal:  Br J Gen Pract       Date:  1995-05       Impact factor: 5.386

10.  A multicenter Italian randomised study on early treatment of Parkinson disease: comparison of L-dopa, l-deprenyl and dopaminoagonists. Study design and short term results. The Italian Parkinson Study Group.

Authors: 
Journal:  Ital J Neurol Sci       Date:  1992-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.